BMO Capital Markets restated their market perform rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report released on Friday morning. The brokerage currently has a $484.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $421.00.
Several other equities analysts have also recently issued reports on REGN. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the company a buy rating in a report on Friday, May 5th. Bank of America Corporation reiterated a buy rating and issued a $593.00 price target (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a report on Friday. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 14th. Morgan Stanley reiterated an equal weight rating and issued a $450.00 price target (up previously from $405.00) on shares of Regeneron Pharmaceuticals in a report on Monday, July 10th. Finally, BidaskClub cut Regeneron Pharmaceuticals from a strong-buy rating to a buy rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, sixteen have given a hold rating and thirteen have assigned a buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of Hold and a consensus target price of $467.38.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at 515.92 on Friday. The firm has a 50-day moving average of $493.24 and a 200-day moving average of $413.36. The firm has a market capitalization of $54.47 billion, a P/E ratio of 62.45 and a beta of 1.67. Regeneron Pharmaceuticals has a one year low of $325.35 and a one year high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same period last year, the company posted $2.57 earnings per share. The firm’s quarterly revenue was up 9.8% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post $12.80 earnings per share for the current fiscal year.
In related news, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neil Stahl sold 8,306 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total value of $4,423,360.30. Following the completion of the sale, the executive vice president now directly owns 43,950 shares in the company, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last three months, insiders sold 59,396 shares of company stock worth $28,484,734. 10.40% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in REGN. Grandfield & Dodd LLC raised its stake in shares of Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $580,000 after buying an additional 17 shares in the last quarter. Opus Point Partners Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 2.3% in the fourth quarter. Opus Point Partners Management LLC now owns 7,684 shares of the biopharmaceutical company’s stock worth $2,821,000 after buying an additional 172 shares in the last quarter. Highbridge Capital Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $323,000. Princeton Capital Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock worth $967,000 after buying an additional 157 shares in the last quarter. Finally, CIBC World Markets Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock worth $8,442,000 after buying an additional 20,833 shares in the last quarter. 66.89% of the stock is currently owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
